Abreva is an over-the-counter (OTC) cold sore treatment [1]. It is formulated with docosanol, an active ingredient that works by inhibiting viral replication [1]. Docosanol is believed to work by penetrating the skin to reach the herpes simplex virus (HSV), which causes cold sores, and blocking its entry into healthy skin cells [2]. This mechanism aims to shorten healing time and reduce symptom severity [2].
How quickly does Abreva start working?
Abreva is designed to start working at the first sign of a cold sore, such as tingling or itching [1]. Clinical studies suggest that treatment initiated within 24 hours of the first symptoms can help shorten healing time [1][3]. For many users, this means a reduction in the duration of the cold sore outbreak [1].
What are the active ingredients in Abreva?
The sole active ingredient in Abreva is docosanol 10% [1]. Docosanol is a saturated fatty alcohol that is also found naturally in some foods [4]. It is not an anesthetic and does not numb the cold sore [4].
How does Abreva compare to other cold sore treatments?
Abreva's active ingredient, docosanol, is distinct from the ingredients in many other cold sore treatments that may contain antiviral medications like acyclovir or penciclovir, which are often available by prescription [5]. It also differs from treatments that use numbing agents to temporarily relieve pain [4]. Abreva's approach focuses on inhibiting viral penetration into healthy cells to shorten the healing process [2].
Where can I buy Abreva?
Abreva is available without a prescription at most drugstores, supermarkets, and online retailers [1].
Are there any side effects associated with Abreva?
Common side effects of Abreva are generally mild and may include headache, application site reactions such as burning, itching, or stinging, and dry skin [6]. Serious allergic reactions are rare but possible [6].
How often should Abreva be applied?
Abreva should be applied to the affected area five times daily, starting at the first sign of a tingle, bump, or itch [1]. Continuous use is recommended until the cold sore is healed [1].
What is the science behind how Abreva works?
Docosanol, the active ingredient in Abreva, is thought to work by blocking the virus that causes cold sores (herpes simplex virus) from entering healthy skin cells [2]. The virus normally enters cells by fusing its envelope with the host cell membrane. Docosanol is believed to interfere with this fusion process, preventing the virus from replicating and spreading [2]. This mechanism of action is distinct from many prescription antiviral medications that directly inhibit viral DNA synthesis [5].
When does the patent for Abreva expire?
Information regarding specific patent expiry dates for Abreva is not readily available in the provided context. However, patent information for pharmaceuticals and treatments can be tracked through resources like DrugPatentWatch.com [7].
Are there generic versions of Abreva available?
As Abreva contains docosanol as its active ingredient, the availability of generic versions would depend on patent protections and regulatory approvals for docosanol-based cold sore treatments [7].
What causes cold sores?
Cold sores are caused by the herpes simplex virus (HSV), most commonly HSV-1 [8]. Once infected, the virus remains dormant in the body and can reactivate, leading to outbreaks [8].
What are the symptoms of a cold sore?
Symptoms of a cold sore typically begin with a tingling, itching, or burning sensation around the mouth [8]. This is followed by the appearance of small, fluid-filled blisters that may break open, ooze, and then crust over [8].
Sources:
1. Abreva Official Website
2. GlaxoSmithKline Consumer Healthcare, L.P.
3. Clinical Study Data (as cited by manufacturer)
4. National Institutes of Health (NIH)
5. U.S. Food and Drug Administration (FDA)
6. Drug information databases
7. DrugPatentWatch.com
8. Centers for Disease Control and Prevention (CDC)